ALLO News and Press, Allogene Therapeutics Inc. From 02/25/21

Presented Initial Phase 1 UNIVERSAL Trial Data on ALLO-715 at The American Society of Hematology (ASH) Meeting Providing First Proof-of-Concept for an AlloCAR T™ Therapy in Relapsed/Refractory Multiple Myeloma Updated ALLO-501 and Initial ALLO-501A AlloCAR T Data in Non-Hodgkin...

The gene editing sector remains red-hot as the promise to transform the way disease is treated. CRISPR Therapeutics seems primed to exploit the technology for outsized share gains. The company faces some intense challenges as will be detailed below. For further details see: ...

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report fourth quarter and f...

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in ...

Stifel analyst Benjamin J. Burnett upgrades Allogene Therapeutics ([[ALLO]] +2.9%) to buy from hold expecting positive reads for the company’s allogeneic CAR T (AlloCAR T™) therapy ALLO-501.The price target is raised to $43, implying ~30.3% upside to the previous close.The analy...

Prestigious Prize Presented to Distinguish Leading-Edge Researchers in Europe Dr. Schumacher Recognized for the Development of Technologies to Study the Role of the Immune System in Cancer Progression and for the Improvement of Cancer Diagnosis and Treatment SOUTH SAN FRANCISCO,...

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this event. For further details see: Allogene Therapeutics (ALLO) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

Shares of allogenic CAR T cell therapy concern Allogene have lost more than 45% of their value since peaking at $55 post-readout of its ALLO-501 candidate. A slightly dilutive secondary and tepid initial results from its BCMA-targeting therapy ALLO-715 are to blame. With significa...

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President...

A Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, Gracell Biotechnologies (GRCL) to raise $150M by offering 8.825M ADSs at a price range of $16 to $18.Underwriters' over-allotment is an additional 1,323,750 ADSs.Net proceeds together with existing cash and cash equiva...